Introduction
Familial Mediterranean fever (FMF) is an autoinflammatory disorder with autosomal-recessive inheritance and high prevalence in ethnic groups overly represented in the Mediterranean basin, including Jewish, Armenian, Arab, and Turkish populations (1) . It is characterized by episodic fever, neutrophilia, and inflammation of the serosal tissues, including pleural, and peritoneal cavities and joints. FMF is caused by mutations in the gene encoding pyrin, also known as MEFV or marenostrin (2, 3) . MEFV translates into a protein of 781 amino acids with an N-terminal pyrin (PYD), a central boxed-box and coiled-coil (BBCC) domain, and a C-terminal PRY/SPRY (B30.2) domain (4) . Nearly one-third of mutations identified in FMF patients are localized to exon 10 (https://infevers.umai-montpellier.fr/ web/search.php?n=1), which encodes for the B30.2 domain. This domain, however, is not found in the murine ortholog (5) . Pyrin was recently identified as an innate sensor that nucleates ASC and caspase-1 to form the multimeric inflammasome complex (6, 7) . Processing of caspase-1 through the inflammasome complex", i.e., is it the processing itself that leads to maturation of inflammatory cytokines, IL-18, and IL-1β, and induction of pyroptotic cell death (8, 9 ). The murine model of FMF involves generation of FMF-knockin (FMF-KI) mouse strain that expresses a chimeric pyrin protein containing the human B30.2 domain with a mutation associated with FMF (5) . The FMF-KI strain, represented as Mefv V726A/V726A , develops an autoinflammatory disorder characterized by systemic wasting and neutrophilia, which is caused by gasdermin-D-mediated IL-1β release in response to aberrant pyrin inflammasome activation (5, 10, 11) . Further, the disorder is mediated through hematopoietic cells, suggesting that pyrin dysfunction is intrinsic to the cells of the immune system (5) . Unlike FMF-KI mice, pyrin-deficient mice do not exhibit an overt developmental or inflammatory defect, but do exhibit reduced epithelial integrity during mucosal damage (12) . Therefore, regulation of pyrin inflammasome during autoinflammatory disorders is critical to maintenance of homeostasis.
Gene expression analysis suggests that pyrin is highly expressed in leukocytes during all stages of development and that its expression is significantly promoted by inflammatory mediators, including TNF (3, (12) (13) (14) (15) . TNF signaling is frequently observed to be heightened in patients with FMF (16) (17) (18) (19) and in the mouse model of FMF (10) . Clinical features of FMF also overlap with TNF receptorassociated periodic syndrome (TRAPS), a class of autoinflammatory disorders associated with mutations in the TNF receptor (20) , and anti-TNF biologics have been used in patients with FMF (21) (22) (23) (24) (25) . These observations suggest that TNF signaling could play an important role in pyrin inflammasomopathy.
TNF is expressed by multiple cells of the innate and adaptive immune systems and by nonimmune cells, such as endothelial cells and fibroblasts (26) . TNF exists in 2 forms -membrane-bound TNF (mTNF, 26 KDa) and soluble TNF (sTNF, 17 KDa), which is produced by TNF-α-converting enzyme-mediated (TACE-mediated) cleavPyrin is an inflammasome sensor that promotes caspase-1-mediated pyroptotic cell death and maturation of proinflammatory cytokines IL-1β and IL-18. Familial Mediterranean fever (FMF), an autoinflammatory disorder, is associated with mutations in the gene encoding pyrin (MEFV). FMF-knockin (FMF-KI) mice that express chimeric pyrin protein with FMF mutation (Mefv
V726A/V726A
) exhibit an autoinflammatory disorder mediated by autoactivation of the pyrin inflammasome. Increase in the levels of TNF are observed in FMF-KI mice, and many features of FMF overlap with the autoinflammatory disorder associated with TNF receptor signaling. In this study, we assessed the contribution of TNF signaling to pyrin inflammasome activation and its consequent role in distinct FMF pathologies. TNF signaling promoted the expression of pyrin in response to multiple stimuli and was required for inflammasome activation in response to canonical pyrin stimuli and in myeloid cells from FMF-KI mice. TNF signaling promoted systemic wasting, anemia, and neutrophilia in the FMF-KI mice. Further, TNF-induced pathology was induced specifically through the TNFR1 receptor, while TNFR2-mediated signaling was distinctly protective in colitis and ankle joint inflammation. Overall, our data show that TNF is a critical modulator of pyrin expression, inflammasome activation, and pyrin-inflammasomopathy. Further, specific blockade of TNFR1 or activation of TNFR2 could provide substantial protection against FMF pathologies. NLRP3 inflammasome activation and subsequent IL-1β release in response to canonical NLRP3 triggers ATP, nigericin, and silica were independent of TNF signaling (Figure 1 , F and G). We also tested to determine whether activation of other inflammasomes, NLRC4 and AIM2, was affected by TNF signaling. Caspase-1 processing and IL-1β release were similar among WT, TNF, and TNFR-deficient BMDMs in response to NLRC4 triggers Salmonella and Pseudomonas and the AIM2 trigger-transfection of DNA analog poly(deoxyadenylic-deoxythymidylic) (poly[dA:dT]) (Supplemental Figure 2 ). These data demonstrate that the TNF/TNFR axis is specifically required to promote pyrin inflammasome activation. Similarly to TLR stimuli, TNF directly induced pyrin expression in WT BMDMs (Figure 2A ). IFN-β stimuli promoted Tnf upregulation ( Figure 2B ) and induced pyrin expression via TNF signaling ( Figure  2A ). The critical role of TNF/TNFR in pyrin expression was additionally observed in peritoneal macrophages under unstimulated conditions and in response to LPS, Pam3CSK4, or IFN-β stimuli ( Figure 2C ). Next, we assessed whether TNF signaling was also in volved in the overt pyrin inflammasome activation observed in Mefv V726A/V726A cells (10) . LPS stimuli induced inflammasome activation in Mefv V726A/V726A monocytes, as assessed by caspase-1 cleavage and IL-1β release (Figure 2 , D-G). Both parameters of inflammasome activation were significantly abrogated in the absence of the TNF signaling axis (Figure 2 , D-G). Similar to the observations with BMDMs, pyrin expression in Mefv V726A/V726A monocytes was also promoted by the TNF/TNFR axis ( Figure 2, D and F) . Overall, these data highlight a central role for TNF in synergizing with multiple stimuli (microbial and IFN-β) to promote pyrin expression and inflammasome activation.
TNF promotes runting and systemic inflammation in FMF mice. We have previously identified inflammasome-mediated IL-1β production as an instigator of pathology in Mefv V726A/V726A mice. Alongside IL-1β, levels of TNF were also significantly elevated in the Mefv V726A/V726A mice in comparison with control Mefv V726A/+ mice ( Figure 3A) , which is consistent with previous reports (5). As TNF signaling was involved in pyrin inflammasome activation ( Figures 1 and 2) , we assessed the contribution of TNF signaling in the FMF disease model by generating Mefv
mice that lack TNF or its receptors, TNFR1 and TNFR2. Loss of TNF signaling provided significant protection against runting, a trait observed in Mefv V726A/V726A mice (10) (Figure 3 , B and C). Mefv V726A/V726A mice lacking TNF or both TNFR1 and TNFR2 gained significantly more weight as compared with the Mefv V726A/V726A mice ( Figure 3 , B and C).
Chronic inflammation is a major driver of systemic wasting, and increased levels of inflammatory mediators are observed in the serum of Mefv V726A/V726A mice (5 Figure 3D ). Other inflammatory mediators, such as IL-6, G-CSF (granulocyte-colony stimulating factor), IL-17, KC, and MCP-1, were significantly higher in Mefv V726A/V726A mice and not age of the proform. Both forms of TNF signal through 2 transmembrane receptors, TNFR1 and TNFR2 (27) . Membrane-bound TNF is a potent ligand for TNFR2 that is expressed mostly by immune cells (27) . On the other hand, TNFR1 is expressed at low levels by most cell types and can respond to both membrane-bound and soluble forms of TNF. Cell death and inflammatory cytokine production in response to TNF signaling is induced primarily by TNFR1 signaling (28) (29) (30) (31) , while the precise role of TNFR2 is relatively unclear (32, 33) . TNFR2 has been shown to promote TNFR1-mediated cell death signaling (29, 34, 35) and, in other cases, to promote cell survival, proliferation, and tissue homeostasis (36) (37) (38) (39) (40) .
In this manuscript, we highlight the central role of TNF signaling in pyrin inflammasome activation and in FMF pathology. TNF played a critical role in promoting expression and activation of pyrin and in the development and amplification of the inflammatory disorder observed in the FMF-KI mice. Further, we demonstrate a pathogenic role of TNFR1 and a distinct, protective role of TNFR2 signaling in FMF pathologies. Overall, the study highlights the specific roles of the TNF/TNFR axis in regulating the pyrin inflammasome and the distinct features of pyrin inflammasomopathy. ) exhibit reduced inflammasome activation, as assessed by lower caspase-1 cleavage, IL-1β maturation, and lactate dehydrogenase (LDH) release consequent to pyroptotic cell death ( Figure 1 , A-C, and Supplemental Figure 1A ; supplemental material available online with this article; https://doi.org/10.1172/ JCI121372DS1). Pyrin expression was significantly upregulated in response to C. difficile toxin stimuli, and this upregulation was mediated by the TNF/TNFR axis ( Figure 1D ). To determine whether C. difficile toxin itself induces TNF production, we assessed the level of TNF transcripts and observed upregulation of TNF mRNA in response to the stimuli (Supplemental Figure 1B) . TNF mRNA was upregulated even in response to commercially available purified toxin (C. difficile toxin B [TcdB]), in accordance with prior reports (41) (Supplemental Figure 1C) . Further, Tnf -/-and Tnfr -/-BMDMs responded with lower caspase-1 processing, IL-18 release, and pyroptotic cell death following purified toxin (TcdB) stimuli (Supplemental Figure 1, D-F ). These data demonstrate the critical role of TNF signaling in pyrin inflammasome activation.
Results

TNF
Pyrin upregulation in response to multiple microbial ligands and cytokine stimuli has been reported previously (15) . We therefore assessed whether TNF signaling is central to pyrin upregulation in response to other TLR and cytokine stimuli. Pyrin expression was significantly upregulated by multiple inflammatory stimuli, including LPS, Pam3CSK4, polyinosinic:polycytidylic acid (poly[I:C]), and gardiquimod, and this upregulation was significantly lower in the absence of TNF/TNFR signaling ( Figure 1E ). Expression of NLRP3, another inflammasome sensor, and cytokine IL-1β, on the other hand, were induced in a manner independent of TNF signaling in response to the same stimuli ( Figure 1E ). Further,
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including lower hematocrit (HCT) and hemoglobin (Hb) levels, were observed in the blood of Mefv V726A/V726A mice and were significantly affected by loss of TNFRs (Table 1) . Further, lower mean corpuscular volume (MCV) and higher red blood cell distribution width (RDW) observed in Mefv V726A/V726A mice are indicative of anemia associated with iron deficiency (47, 48) . These alterations were mildly but significantly restored with the loss of TNF or simultaneous loss of TNFR1 and TNFR2 (Table 1) . Oversignificantly affected by the loss of TNF signaling ( Figure 3D ). While the genetic loss of IL-1β completely rescued Mefv V726A/V726A mice from systemic wasting and inflammation (10), loss of TNF significantly reduced the production of specific inflammatory mediators, including IL-1β, and the extent of systemic wasting.
Anemia is observed in patients with FMF (42), and inflammatory cytokines including TNF have been ascribed an inhibitory role in erythropoiesis leading to anemia (43) (44) (45) (46) . Features of anemia, Figure 3 ). These data demonstrate that neutrophilia and extramedullary granulopoiesis in Mefv V726A/V726A mice are specifically promoted through TNF signaling.
Neutrophilia in FMF mice is driven by hematopoietic cells (5), and since TNF is a critical driver of neutrophilia (Figure 4) , we assessed whether TNF production by or TNFR signaling within the hematopoietic compartment was required to drive neutrophilia in Mefv V726A/V726A mice. To address this, we generated BM chimeras with WT mice as recipients and Mefv (1, 5) , and TNF has been shown to directly promote myelopoiesis (49) . Neutrophilia, as ascertained by the proportion and number of circulating neutrophils, was significantly reduced in the absence of TNF signaling in Mefv Table 1 ). Mefv V726A/V726A mice further exhibited extramedullary granulopoiesis in the liver ( Figure 4C ) and spleen ( Figure 4D ) that was also significantly reduced in the absence of TNF signaling. While loss of TNF signaling did not protect against splenomegaly ( Figure 4E mice too was mediated specifically through TNFR1 ( Figure 6C ). While splenomegaly was not significantly rescued by loss of TNFR1 ( Figure 6D ), the number of granulocytes in spleens of Mefv V726A/V726A mice was significantly reduced by specific loss of TNFR1 ( Figure  6E ). Therefore, these pathogenic effects of TNF in Mefv
mice are mediated specifically through TNFR1 signaling.
TNFR2 signaling is protective against colitis and arthritis in Mefv
V726A/V726A mice. Serosal inflammation, including inflammation in the colon and joints, has been observed in both FMF patients (50) and the murine model of FMF (5) . We have previously shown that IL-1β protects against serosal tissue inflammation in Mefv V726A/V726A mice (10). Since anti-TNF therapies have been used TNFR-deficient donor cells (Mefv V726A/V726A Tnfr -/->>WT) (Supplemental Figure 4 ). These data demonstrate that TNF produced by hematopoietic cells acts on stromal cells to promote neutrophilia in Mefv V726A/V726A mice. TNFR1 promotes systemic wasting, anemia, and neutrophilia in Mefv V726A/V726A mice. TNF is known to signal through both TNFR1 and TNFR2 (44) . To assess their relative function in FMF pathologies, we generated Mefv V726A/V726A mice lacking either TNFR1 or TNFR2. The loss of TNFR1 alone was sufficient to reduce systemic wasting in Mefv V726A/V726A mice ( Figure 5, A and B) . Similar to systemic wasting, parameters of anemia -Hb, HCT, MCV and RDW levels -that were altered in the Mefv V726A/V726A mice were ameliorated by genetic deletion of TNFR1, while TNFR2 was largely dispensable ( Figure 5C ). Furthermore, deficiency of TNFR1 prevented neutro- in the treatment of inflammatory disorders, including colitis and arthritis, we theorized that TNF signaling would be particularly important in colon and joint inflammation. The colon tissue was assessed for histological perturbations, and colons from Mefv V726A/V726A mice exhibited substantial inflammation characterized by immune cell infiltration in both the mucosa and submucosa. While the genetic loss of TNF or TNFR1 provided significant protection against colonic inflammation, the absence of TNFR2 exacerbated inflammation in the colons of Mefv V726A/V726A mice ( Figure  7, A and B) . Further, loss of TNFR2 also negated the protection provided by loss of TNFR1, and mice with concomitant loss of both TNFR1 and TNFR2 displayed inflammation comparable to that of Mefv V726A/V726A mice ( Figure 7, A and B) . In addition to colitis, Mefv V726A/V726A mice exhibited joint inflammation that was visibly discernible in the hind limbs of the mice ( Figure 7C ). Ankle inflammation (in the form of joint swelling) was observed in about 50% of Mefv V726A/V726A mice, 63 % of Mefv
, and 53 % of Mefv V726A/V726A Tnfr1 -/-Tnfr2 -/-mice ( Figure  7C ). Genetic deletion of TNF or TNFR1 was protective against the joint pathology, with none of the TNF-or TNFR1-deficient Mefv V726A/V726A mice exhibiting joint inflammation ( Figure 7C ). These data demonstrate that TNF/TNFR1 signaling promotes colitis and joint inflammation in the FMF model, while TNFR2 signaling is protective. Further, the protection provided by absence of TNFR1 was lost with simultaneous deletion of TNFR2 (Figure 7 ). Therefore, TNRF1 and TNFR2 function distinctly to alter serosal and systemic inflammation in Mefv V726A/V726A mice. Given that the loss of TNFR1 does not protect Mefv V726A/V726A mice lacking TNFR2, the protection conferred by TNFR2 signaling is unlikely to be mediated through sequestration of TNF or inhibition of the pathogenic TNFR1-mediated signal.
One of the major antiinflammatory roles ascribed to TNFR2 signaling includes stability of Tregs (51, 52) . TNFR2 agonists have been used as a strategy to boost Treg response (53) . We therefore assessed whether loss of TNFR2 affected the proportion of Tregs in Mefv V726A/V726A mice. The proportion of Tregs was significantly increased in both the spleens and popliteal LNs (pLN) of Mefv V726A/V726A mice and was reduced with simultaneous deletion of both TNFR1 and TNFR2 (Supplemental Figure 5) . The loss of TNFR2 alone, however, did not result in a similar decrease in the proportion of Tregs (Supplemental Figure 5) . Within the pLN, the proportion of Tregs was instead significantly enhanced in the absence of TNFR2 (Supplemental Figure 5) . Therefore, the proportion of Tregs correlated with the extent of inflammation and was not intrinsically regulated by TNFR2. These data preclude the loss of Tregs as the mechanism for increased colitis and joint inflammation in Mefv V726A/V726A mice lacking TNFR2.
Discussion
In this manuscript, we demonstrate that the TNF/TNFR axis plays a critical role in pyrin inflammasome activation in response to a canonical stimulus and in a gain-of-function mutation model. TNF signaling is critical to pyrin expression in response to inflammatory triggers in cells of myeloid lineage. TNF mRNA is detectable during macrophage differentiation (54) , and mTNF is expressed basally in differentiated macrophages (55) . Therefore, the role of the TNF/TNFR axis in pyrin expression in macrophages could be a result of both basal and induced TNF signaling. The TNF/TNFR axis further promoted the inflammatory disorder in Mefv V726A/V726A mice that exhibit aberrant pyrin inflammasome activation (10) . We have previously shown that TNF production in Mefv V726A/V726A mice was abrogated in mice lacking the ASC/Casp1/IL-1β axis (10) . The data presented in this manuscript propose a feedback loop for the TNF/pyrin inflammasome axis, with TNF signaling and inflammasome activation synergistically amplifying the inflammatory response. This also suggests that pyrin inflammasome-mediated IL-1β promotes TNF production to modulate certain features of FMF pathology (Supplemental Figure 6) . The intersection of TNF with IL-1 cytokines has also been observed in other autoinflammatory models, including neutrophilic dermatosis (56) and skin inflammation (57) (58) (59) . A recent study reported that TNF promotes expression of inflammasome components and inflammatory disease in a mouse model of NLRP3 inflammasomopathy (60, 61) . However, similarly to what was shown in a prior report (62), we found no role for TNF in promoting NLRP3 expression or inflammasome activation in BMDMs. TNF could, however, affect expression and activation of NLRP3 under inflammatory conditions observed in autoinflammatory models.
Further, the pathogenic role of TNF in Mefv V726A/V726A mice is mediated through TNFR1 while TNFR2 signaling is protective against certain pathologies, including arthritis and colitis. TNF/TNFR1 signaling is involved in proinflammatory cytokine production through NF-κB and MAPK activation and in proapoptotic signaling through the RIPK3/CASP8 axis (63) . We have previously shown that, unlike TNFR1 signaling, lack of the While the loss of TNF/TNFR signaling provided substantial protection against all disease characteristics, it was particularly effective against neutrophilia. We further demonstrated that TNF produced by hematopoietic cells is a critical driver of neutrophilia in Mefv V726A/V726A mice. Granulocyte-derived TNF has been recently shown to promote vascular remodeling and hematopoietic recovery during BM transplantation (67) . The specific role of TNFR1 signaling in neutrophilia in Mefv V726A/V726A mice is consistent with previous studies that show that TNFR1, but not TNFR2, synergizes with GM-CSF to promote granulocyte differentiation (49, 68) . Additionally, it was interesting that neutrophilia in Mefv V726A/V726A mice lacking TNF signaling was reduced despite significant levels of neutrophilia-promoting mediators, such as G-CSF, KC, and IL-17, in these mice ( Figure 3D ). However, TNF can modulate hematopoiesis (49, 68) , expression of adhesion molecules (69, 70) , and neutrophil chemotaxis and apoptosis (71, 72) , and it is likely that neutrophilia in FMF mice is affected by these functions of TNF signaling.
Distinct, synergistic, and opposing functions of TNFR1 and TNFR2 have been demonstrated in various models, including sepsis (73), TNF-induced cutaneous inflammation (74, 75) , skin necrosis (76), collagen-induced arthritis (77) , and experimental autoimmune encephalomyelitis (EAE) (78) . TNF-overexpressing mice exhibit arthritis and colitis that is mediated by TNFR1, but protected by TNFR2-mediated signaling (79) . We observed that RIPK3/CASP8 axis does not provide any protection against FMF disease, indicating that TNFR1-mediated cell death is not relevant to disease progression in this model (10) . TNF-mediated inflammation, therefore, might be the critical pathogenic function mediated by TNFR1 signaling. It was further surprising and interesting that the loss of TNFR2 increases disease severity in colon and joints without exacerbating systemic disease. This suggests that the systemic disease features, including weight loss and neutrophilia, are dominantly modulated by TNFR1 signaling and that the status of TNFR2 expression has no significant effect. Based on these observations, it is clear that the overall disease outcome depends on the significance and balance of signaling via TNFR1 or TNFR2. TNF blockade is being used as a therapy for treatment of inflammation-associated amyloidosis and proteinuria in patients with FMF that do not respond to colchicine (23-25, 64, 65) . Distinct features of the disease, including arthritis (21, 61) and abdominal inflammation (21), have been treated by specific targeting of sTNF, which has a higher affinity for TNFR1 while leaving mTNF signaling intact (22, 66) . Selective targeting of TNF to restrict TNFR1 inflammatory programming while keeping the antiinflammatory function of TNFR2 intact could be particularly beneficial for treatment of specific ailments associated with FMF and needs to be explored further as a therapeutic strategy. mice, however, was surprising, as loss of TNF does not phenocopy the simultaneous loss of TNFR1 and TNFR2. We propose that TNFR2 exhibits its protective function through interaction with ligands other than TNF. Lymphotoxin is known to signal through TNFRs (1 and 2) (80, 81), and even a TNF-and lymphotoxin-independent role for TNFR2 signaling has been previously reported (82) . Similarly, TNFindependent and antagonistic functions of the 2 TNF receptors have been previously reported in retinal ischemia (83) . Specific targeting of TNFR2 is being investigated as a therapeutic strategy for treatment of type 1 diabetes (53), graft -versushost disease (84) , and cancer (85) . Therefore, delving into the precise effect of specific TNF signaling (through TNFR1 or TNFR2) in various autoinflammatory disorders is an important area of research.
Overall, our data demonstrate a critical role for TNF in FMF pathologies and describe the protective and pathogenic features of TNF/TNFR signaling. Our data further point to selective TNF targeting for distinct inflammatory features in autoinflammatory disorders such as TRAPS and inflammasomopathies FMF.
Methods
Mice. Mefv
V726A/+ and Mefv V726A/V726A mice have been previously described (5) lacking each of these components. Cellular processing and analysis. Mice were monitored weekly for weight gain starting from 3 to 4 weeks of age and euthanized at 8 to 12 weeks of age for systemic analysis. Blood was collected through a cardiac puncture, and 50 μl was added to anticoagulant EDTA for cellular analysis. The spleen and LNs were homogenized and passed through a 40 μm filter to obtain a single-cell suspension. Both blood and spleen the absence of TNFR2 did not promote organ-specific inflammation through loss of Tregs. Further, the arthritis in TNFoverexpressing mice is independent of the adaptive immune system (79) . This suggests that the protective role of TNFR2 in the colon and joint inflammation in Mefv V726A/V726A mice is independent of TNF signaling and Treg stability. TNFR2 additionally did Histology and microscopy analysis. Liver and colon were fixed in 10% formalin, embedded in paraffin, sectioned, and stained with mice. The numbers below each image represent the proportion of mice in which joint inflammation was visibly discernible. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001 compared with Mefv V726A/V726A , 2-way ANOVA followed by Fischer's LSD test.
jci.org Volume 129 Number 1 January 2019 tease inhibitors and phosphatase inhibitors (Millipore) and boiled in SDS sample buffer for Western blot analysis. Caspase-1 activation was assessed by Western blot using the anti-caspase-1 p20 antibody (AG-20B-0042-C100, Adipogen), as previously described (62) . See complete unedited blots in the supplemental material. For analysis of pyrin expression, BMDMs were stimulated with 200 ng/ml LPS (InvivoGen), 1 μg/ml Pam3CSK4 (InvivoGen), 5 μg/ ml high-molecular weight poly(I:C) (InvivoGen), 50 ng/ml TNF (Peprotech), and 500 U/ml IFN-β (PBL assay Science) for indicated periods of time and processed for immunoblot analysis, as previously described (62) . The antibodies used for probing included pyrin (catalog ab195975, Abcam), NLRP3 (catalog AG-20B-0014, Adipogen), IL-1β (R&D Systems), and β-actin (Cell Signaling Technology), and secondary anti-rabbit, anti-mouse, or anti-goat HRP antibodies (Jackson ImmunoResearch Laboratories).
ELISA. Cytokines in the serum and cell-culture supernatants were measured by ELISA, according to the manufacturers' instructions. The IL-1β and multiplex ELISA kits were obtained from Thermo Fisher and Millipore, respectively.
LDH assay. LDH assay (Promega) was carried out per the manufacturer's instructions. Briefly, LDH release was assessed in the cell-culture supernatants by incubating with the substrate at 37°C for 15 minutes. End-point measurement was conducted by reading the plate at 450 nM. A standard curve was similarly generated, and sample spectrometric values were converted to percentage cell death using the curve.
Statistics. All statistical analysis was performed using Prism 6.0 software. Student's t test or 1-way ANOVA was used with Fischer's least significance difference (LSD) or Dunn's post test, as indicated. Two-way ANOVA was used to analyze the kinetics of body weight gain. In most analyses, Mefv V726A/V726A mice were used as a control to demonstrate degree of disease or protection. P values of less than 0.05 were considered significant. Study approval. Mice were maintained in a specific pathogen-free facility, and animal studies were approved by the St. Jude Children's Research Hospital Committee on the Use and Care of Animals.
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Area affected was graded as follows: normal, rare or inconspicuous lesions; minimal, less that 5% of area affected; mild, multifocal or small, focal, or widely separated, but conspicuous lesions with 5% to 10% involvement; moderate, multifocal, prominent lesions with 10% to 50% involvement; marked, coalescing to extensive lesions or areas of inflammation with some loss of structure with 50% to 90% involvement; and severe, diffuse lesion with effacement of normal structure and over 90% involvement. These categories were scored as 0, normal; 1, minimal; 15, mild; 25, moderate; 40, marked; and 80, severe. Area affected or extent of inflammation scores across proximal, middle, and distal regions of the colon were added to get a cumulative area affected score.
Immunofluorescence. Splenic tissue was fixed in 2% paraformaldehyde for 24 hours followed by cryoprotection with 20% sucrose before embedding in OCT medium. Cryosections that were 10 μm thick were blocked by incubation in TBS containing 2% BSA and 5% normal goat serum for 30 minutes prior to incubation with AF488-conjugated anti-B220 (BioLegend; clone RA3-6B2), AF594-conjugated anti-Ly6C (BioLegend; clone HK1.4), and AF647-conjugated anti-CD3 (BioLegend; clone 17A2) overnight at 4°C. Slides were washed for 15 minutes in TBS prior to mounting with ProLong Gold Diamond Antifade Mountant (Thermo Fisher Scientific). Fluorescent images were acquired using an inverted TiE microscope (Nikon) equipped with a 0.75 NA ×20 objective and an iXon Ultra EMCCD camera and analyzed using NIS Elements software (Nikon Instruments).
Toxin preparation. C. difficile toxin was prepared as previously described (87) . Briefly, C. difficile strain r20291 (AB -and AB + ) was cultured in tryptone-yeast extract media for 24 hours in an anaerobic chamber at 37°C. Cultures were diluted to an OD that corresponds to 2 × 10 7 CFU/ml and spun down; the supernatant was sterilized using 0.22 μM filters. Supernatant prepared from toxin-negative (control) and toxinpositive strain was used to stimulate BMDMs at a 1:5 dilution.
Purified TcdB was obtained from List Biological Laboratories (catalog 155) and used at final concentration of 0.5 μg/ml, as previously described (7) .
Cell culture and stimulation. Monocytes were obtained by culturing cells from BM in DMEM media (Thermo Fisher) supplemented with 30% media conditioned by L929 fibroblasts, 10% FBS, nonessential amino acids (NEAAs), and penicillin-streptomycin for 3 days. Nonadherent monocytes were collected, counted, and plated at a density of 1 × 10 6 cells per ml for stimulation. Cells were stimulated with 200 ng/ml LPS (InvivoGen) for 24 hours. BMDMs were generated as previously described (62) . For pyrin activation, cells were resuspended in opti-MEM (Thermo Fisher) media and stimulated with C. difficile supernatant (AB -and AB + ) for 16 hours. For NLRP3 activation, cells were primed with LPS (200 ng/ml) for 4 hours followed by ATP (5 mM), nigericin (1 μM), and silica (250 μg/ml) for 30 minutes, 2 hours, and 12 hours, respectively. For NLRC4 activation, cells were stimulated with log-phase Salmonella and Pseudomonas at an MOI of 1 for 4 hours. For AIM2 activation, cells were primed with LPS (200 ng/ml) for 4 hours, followed by transfection of dsDNA (2.5 μg/ml) using lipofectamine, as previously described (88) . At the end of stimulation, 120 μl supernatant was removed for ELISA. Cells and supernatants were then lysed with RIPA buffer containing pro-
